NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free MRNS Stock Alerts $1.31 +0.02 (+1.55%) (As of 11:09 AM ET) Add Compare Share Share Today's Range$1.30▼$1.3450-Day Range$1.20▼$9.3952-Week Range$1.11▼$11.26Volume388,137 shsAverage Volume1.44 million shsMarket Capitalization$71.96 millionP/E RatioN/ADividend YieldN/APrice Target$13.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marinus Pharmaceuticals alerts: Email Address Marinus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside968.7% Upside$13.79 Price TargetShort InterestBearish9.10% of Shares Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector152nd out of 920 stocksPharmaceutical Preparations Industry60th out of 430 stocks 4.3 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Marinus Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.10% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 10.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 60.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.55. Previous Next 1.7 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Marinus Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -92% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.87) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Marinus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesMay 20 at 9:29 PM | msn.comMarinus Pharmaceuticals Completes Enrollment for Phase 3 Trial on Tuberous Sclerosis ComplexMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: Marinus Pharmaceuticals’ Advancements and Long-term Patent Protection Signal Strong ProspectsMay 17, 2024 | businesswire.comMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramMay 13, 2024 | americanbankingnews.comFY2027 EPS Estimates for Marinus Pharmaceuticals, Inc. Cut by HC Wainwright (NASDAQ:MRNS)May 13, 2024 | americanbankingnews.comResearch Analysts Set Expectations for Marinus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MRNS)May 11, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost ManagementMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)May 8, 2024 | washingtonpost.comMarinus Pharmaceuticals: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug TrialsMay 8, 2024 | msn.comMarinus Pharmaceuticals GAAP EPS of -$0.68 misses by $0.02, revenue of $7.68M misses by $1.48MMay 8, 2024 | msn.comMarinus Pharmaceuticals CEO to Speak at RBC Healthcare ConferenceMay 8, 2024 | finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 2, 2024 | businesswire.comMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceMay 1, 2024 | finance.yahoo.comMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024April 24, 2024 | investing.comMarinus Pharmaceuticals Inc (MRNS)April 17, 2024 | msn.comBaird Downgrades Marinus Pharmaceuticals (MRNS)April 16, 2024 | msn.comRBC Capital Downgrades Marinus Pharmaceuticals (MRNS)April 15, 2024 | markets.businessinsider.comMaintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial HealthApril 15, 2024 | bizjournals.comMarinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidateApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | markets.businessinsider.comMarinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionApril 15, 2024 | msn.comWhy Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?April 15, 2024 | investorplace.comWhy Are Stocks Up Today?See More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/23/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees165Year FoundedN/APrice Target and Rating Average Stock Price Target$13.79 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+968.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-513.80% Pretax Margin-519.24% Return on Equity-518.13% Return on Assets-81.85% Debt Debt-to-Equity Ratio5.68 Current Ratio3.07 Quick Ratio2.93 Sales & Book Value Annual Sales$30.99 million Price / Sales2.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-4.30Miscellaneous Outstanding Shares54,930,000Free Float51,935,000Market Cap$70.86 million OptionableOptionable Beta1.14 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 61)CEO, President & Chairman Comp: $1.01MDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSenior VP of Investor Relations, Human Resources & Corporate AffairsMs. Martha E. Manning Esq. (Age 69)J. D., Senior VP, General Counsel & Secretary Molly CameronDirector of Corporate Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Business OfficerMr. David CzekaiSenior Vice President of Chemistry, Manufacturing & ControlsDr. Mark Paternoster Ph.D.Senior Vice President of DevelopmentDr. Dayong Li Ph.D.Senior Vice President of BiometricsMore ExecutivesKey CompetitorsTempest TherapeuticsNASDAQ:TPSTCheckpoint TherapeuticsNASDAQ:CKPTBioXcel TherapeuticsNASDAQ:BTAIEledon PharmaceuticalsNASDAQ:ELDNLandos BiopharmaNASDAQ:LABPView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 212,200 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCSold 8,200 shares on 5/17/2024Ownership: 0.000%Bain Capital Life Sciences Investors LLCSold 37,678 shares on 5/16/2024Ownership: 2.537%Jacobs Levy Equity Management Inc.Bought 42,449 shares on 5/16/2024Ownership: 0.077%Torno Capital LLCBought 200 shares on 5/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MRNS Stock Analysis - Frequently Asked Questions Should I buy or sell Marinus Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks. What is Marinus Pharmaceuticals' stock price target for 2024? 7 brokers have issued 12 month price targets for Marinus Pharmaceuticals' stock. Their MRNS share price targets range from $3.00 to $28.00. On average, they predict the company's share price to reach $13.79 in the next year. This suggests a possible upside of 968.7% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts. How have MRNS shares performed in 2024? Marinus Pharmaceuticals' stock was trading at $10.87 at the beginning of 2024. Since then, MRNS stock has decreased by 88.1% and is now trading at $1.29. View the best growth stocks for 2024 here. When is Marinus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our MRNS earnings forecast. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its quarterly earnings results on Tuesday, March, 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.10. The biopharmaceutical company earned $7.19 million during the quarter, compared to analysts' expectations of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative trailing twelve-month return on equity of 518.13%. During the same quarter last year, the business earned ($0.76) EPS. What ETFs hold Marinus Pharmaceuticals' stock? ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals's stock reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO). Who are Marinus Pharmaceuticals' major shareholders? Marinus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (7.54%), Vanguard Group Inc. (5.11%), Bain Capital Life Sciences Investors LLC (2.54%), Ikarian Capital LLC (0.00%), Hussman Strategic Advisors Inc. (0.13%) and Jacobs Levy Equity Management Inc. (0.08%). Insiders that own company stock include Christina Shafer, Martha E Manning, Scott Braunstein, Seth H Z Fischer and Steven Pfanstiel. View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRNS) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersDividend-like income from non-dividend stocksUnstoppable ProsperityMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeThis could mean the end of the U.S dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyGold Set to EXPLODE!Gold Safe Exchange$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.